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There is a need to develop quick, cheap, sensitive and specific methods to detect the carcinogenic potential of chemicals. Currently there 10 
is no in vitro model system for reliable detection of non-genotoxic carcinogens (NGTX) and current tests for detection of genotoxic 
carcinogens (GTX) can have low specificity. A transcriptomics approach holds promise and a few studies have utilised this technique. 
However, the majority of these studies have examined liver carcinogens with little work on renal carcinogens which may act via renal-
specific NGTX mechanisms. In this study the normal rat renal cell line (NRK-52E) was exposed to sub-toxic concentrations of selected 
rat renal carcinogens and non-carcinogens (NC) for 6h, 24h and 72h. Renal carcinogens were classified based on their presumed mode of 15 
action into GTX and NGTX classes. A whole-genome transcriptomics approach was used to determined genes and pathways as potential 
signatures for GTX, NGTX and those common to both carcinogenic events in vitro. For some of the GTX compounds an S9 drug 
metabolising system was included to aid pro-carcinogen activation. Only three genes were deregulated after carcinogen (GTX + NGTX) 
exposure, one Mdm2 with a detection rate of 67%, and p21 and Cd55 with a detection rate of 56%.  However, examination of enriched 
pathways showed that 3 out of 4 NGTX carcinogens and 4 out of 5 GTX carcinogens were related to known pathways involved in 20 
carcinogenesis giving a detection rate of 78%. In contrast, none of the NC chemicals induced any of the above genes or well-established 
carcinogenic pathways. Additionally, five genes (Lingo1, Hmox1, Ssu72, Lyrm and Usp9x) were commonly altered with 3 out of 4 
NGTX carcinogens but not with NC or GTX carcinogens. However, there was no clear separation of GTX and NGTX carcinogens using 
pathway analysis with several pathways being common to both classes. The findings presented here indicate that the NRK-52E cell line 
has the potential to detect carcinogenic chemicals, although a much larger number of chemicals need to be used to confirm these 25 
findings.  
 
Introduction 
Current evaluation as to whether a chemical is carcinogenic is 
dependent on the outcome of chronic rodent bioassays, which 30 
involves administering the compound at maximum tolerated 
doses for its lifetime, typically two years. At present, a 
conventional rodent study takes up to five years, costs €1.5 – 3 
million per chemical tested and consumes about 800 mice and 
rats1.  35 
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The last 50 years of animal data suggests that carcinogenic 50 
compounds can be divided, based on their mode of action (MOA) 
into two classes, genotoxic (GTX) and non-genotoxic (NGTX)2. 
GTX carcinogens are readily detected using a number of short-
term bacterial and cultured mammalian cell assays and although 
these assays are very sensitive, a problem of low speciﬁcity exists 55 
3-5.NGTX carcinogens, however, are more problematic and 
depend in most cases on the outcome of a two-year rodent 
bioassay. Although some in vitro tests are available6, currently 
there is no accurate in vitro model that can predict the 
carcinogenic potential of NGTX chemicals. Each year, several 60 
thousand new chemicals are entering the world markets and 
additionally under the Registration, Evaluation, Authorization 
and restriction of Chemicals (REACH) initiative there is a need to 
validate the toxicity of an estimated 68,000 chemicals7. High-
throughput technologies such as whole-genome gene expression 65 
profiling have opened the way to understand the systemic 
response to a toxic insult and also might speed up the process of 
risk assessment8-9. 
In this study, the Normal Rat Kidney Epithelial cell line (NRK-
52E) was exposed to eleven carcinogens and five non-70 
carcinogens (NC) at their IC10 concentration at 72h for 6h, 24h 
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and 72h. The selected renal carcinogens, all known to induce 
cancer in rats, were classified based on their presumed MOA into 
GTX, NGTX and NC classes10. From the selected GTX 
compounds, two have been classified by International Agency for 
Research on Cancer (IARC) as carcinogenic to human (Group 1), 5 
aristolochic acid and benzo(a)pyrene. One, dimethylnitrosamine 
to Group 2A, probable human carcinogen, and three, 2-
nitrofluorene, streptozotocin and potassium bromate to Group 2B, 
possible human carcinogen. The five NGTX carcinogens selected 
for this study are all chlorinated chemicals. Three of them, 10 
bromodichloromethane, chlorothalonil and ochratoxin A are 
classified as Group 2B while monuron is classified as Group 3, 
not carcinogenic to humans. S-(1,2-dichlorovinyl)-L-cysteine is a 
non-classified metabolite of trichloroethylene (which itself 
belongs to Group 2A). As a control five NC, mainly widely used 15 
pharmaceuticals, clonidine, D-mannitol, diclofenac sodium, 
nifedipine and tolbutamide were used. Many GTX carcinogens 
undergo some degree of metabolism in order to interact with 
DNA11-12. NRK-52E cells have poor cytochrome P450 drug 
metabolising capability13 (HPLC-MS/MS; Bloch, unpublished 20 
results), so additional studies were conducted with and without 
pre-incubation with rat liver β-naphthoflavone-induced S9 
fraction. After 6h, 24h and 72h of exposure the total RNA was 
isolated, purified, quality checked and whole-genome gene 
expression changes were determined using Affymetrix Rat 25 
GeneChip 230 2.0. In addition to alteration in transcriptome 
profile, DNA damage was determined by conducting the 
cytokinesis-blocked micronucleus assay14. 
Materials and Methods 
Chemicals 30 
All test chemicals were purchased from Sigma-Aldrich, UK, 
except for S-(1,2-dichlorovinyl)-L-cysteine which was a gift from 
D. Moore, formerly of Syngenta Central Toxicology Laboratory, 
Alderley Park, Cheshire. β-naphthoflavone-induced rat liver S9 
was purchased from Celsis, In Vitro Technologies, Belgium. 35 
Cell culture  
NRK-52E cells (ATCC, CRL-1571) were cultured in Dulbecco’s 
Modified Eagle Medium (DMEM) with 10% fetal calf serum and 
penicillin 100 I.U./ml, streptomycin solution 100 µg/ml in a 
humidified 5% CO2 incubator at 370C. For cytotoxicity and 40 
transcriptomics studies, cells were sub-cultured in 6-well plates in 
medium without serum until 80% confluent and then exposed to 
selected compounds dissolved in DMSO (0.1%v/v) or medium 
(in case of potassium bromate).  
Generation of IC10 45 
A dose-response curve for cytotoxicity using LDH leakage and 
the MTT assay15 was generated for each compound after 24h and 
72h exposure using cells exposed to medium or DMSO alone as 
the 100% value. At least three separate experiments were 
conducted with each compound. The dose that caused 50 
approximately 10% cytotoxicity (IC10) at 72h was selected for the 
transcriptomics studies. The doses selected were as follows: GTX 
compounds; 1.65μM, aristolochic acid (AA); 40μM, 
benzo(a)pyrene (BaP); 20μM, 2-nitrofluorene (2NF) and 500μM, 
potassium bromate (KBrO3).  NGTX compounds; 470μM, 55 
bromodichloromethane (BDCM); 1.1μM, chlorothalonil (CHL); 
3μM, S-(1,2-dichlorovinyl)-L-cysteine (DCVC); 250μM, 
monuron (MON) and 0.5μM, ochratoxin A (OTA).  NC 
compounds were; 1.12mM, clonidine (CLO); 6μM, diclofenac 
sodium (DS); 35μM, nifedipine (NIF) and 370μM, tolbutamide 60 
(TOL). The GTX compounds; dimethylnitrosamine (NDMA), 
streptozotocin (STZ) and NC; D-mannitol (MAN) were not 
cytotoxic to NRK-52E cells and used at a dose of 1mM, 5mM 
and 10mM respectively. After 6h, 24h and 72h the medium was 
removed and the cells taken for RNA extraction, three studies 65 
were conducted at each time point with each compound. 
Incorporating an enhanced xenobiotic capability 
The IC10 concentration for three GTX compounds was 
determined in the presence of S9 over 72h as described above. 
The IC10 concentrations were as follows: BaP (87µM), STZ 70 
(350µM) and 2NF (70µM). Compounds were pre-incubated in 
either the presence or absence of rat liver β-naphthoflavone-
induced S9 metabolising system for 3h at 370C. The S9 
metabolising system was prepared by diluting the S9 fraction to 
10mg protein/ml with ice-cold Tris buffer, (60mM, pH 7.4). The 75 
NADPH regenerating system consisted of ice-cold NaHCO3 (2% 
(w/v), NADP+ (1.7mg/ml), glucose-6-phosphate (7.8mg/ml) and 
glucose-6-phosphate dehydrogenase (6units/ml) which was 
prepared immediately before use. The reaction mixture contained 
S9 fraction 10mg/ml (0.1ml), 60mM Tris buffer, pH 7.4 (0.64ml), 80 
NADPH regenerating system (0.25ml) and the reaction was 
started by the addition of DMSO or tested compound dissolved in 
DMSO (0.01ml). The reaction was stopped after 3h by heating to 
60°C then cooled on ice and added to ~80% confluent NRK-52E 
cells growing in 1ml medium in 6 well-plates. After 72h the 85 
medium was removed and the cells taken for RNA extraction, 
with three studies conducted with each compound. 
Cytokinesis –Block Micronucleus Assay 
NRK-52E cells were seeded on glass slides and exposed to GTX 
or NGTX compounds at the IC10 concentration at 72h together 90 
with cytochalasin B (3µl/ml of a 1mg/ml stock solution in 
DMSO) in 1ml medium for 24h. Compounds were dissolved in 
DMSO, with the exception of KBrO3 which was dissolved in 
medium. The cells were fixed with 37% (v/v) formaldehyde 
(0.1ml) in hypotonic solution (0.4% Na-citrate/0.4% KCl 1:1 95 
v/v)(2.4ml) and incubated for 8 min at 4°C. The cells were then 
washed with a solution containing equal volumes of hypotonic 
solution (Na citrate/KCl) and fixative (methanol (100%): acetic 
acid (100%) 4:1v/v). Then 50% of the hypotonic/fixative mixture 
was removed and fixative alone was gently added. The mixture 100 
was then removed and 100% fixative was added and left for at 
least 3 min. The slides were than air-dried and immersed for 15 
min in 10μM DAPI solution in distilled water. After air-drying 
the slides were mounted with a cover slip for microscopy. 
Around 3,000 binucleated cells from at least three replicates were 105 
analyzed for the presence of micronuclei (MN) using an 
automated MN scoring system Metafer (MetaSystems). Control 
cells with DMSO (or medium alone) were compared to treated 
cells. For some studies, the cells were pre-incubation with rat 
liver S9 fraction either alone or in the presence of a GTX 110 
carcinogen as described above. Statistical analysis was performed 
between the relevant control and test compound using a paired t-
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test (GraphPad InStat) with a p value <0.05 considered 
significant.    
RNA isolation and microarray 
Total RNA was isolated from control and compound treated 
NRK-52E cells with trizol reagent (Invitrogen) and purified using 5 
the RNeasy Total RNA Mini Kit (Qiagen) according to 
manufacturer's instructions. Purified total RNA was checked for 
purity and integrity using a Agilent 2001 Bioanalyzer (Agilent 
Technologies GmbH, Germany) before processing. All RNA 
used in this study had values of 1.9-2.0 as measured by A260/A280 10 
ratio, and RIN values from 9-10. The integrity of RNA was also 
checked by gel electrophoresis with result showing a clear 2:1 
ratio of 28S rRNA to 18S rRNA. The amount of RNA was 
around 1-5μg. Transcriptomics data was generated using 
Affymetrix GeneChip Rat Genome 230 2.0 Arrays. 15 
Three replicates were used for each compound and control and at 
each time point.. 
Microarray Hybridization 
Target preparation 
cDNA was prepared using the Affymetrix IVT express kit 20 
(Affymetrix, Santa Clara). cDNA synthesis and labelling was 
performed according to the manufacturer's procedures. 
Subsequent labelling of the samples was conducted by synthesis 
of Biotin-labelled complementary RNA (cRNA) using the 
GeneChip IVT labelling kit (Affymetrix). Purified cRNA was 25 
quantified using a spectrophotometer, and unfragmented samples 
were checked on the Bioanalyzer. Subsequently, cRNA samples 
were fragmented for target preparation according to the 
Affymetrix manual and checked on the Bioanalyzer. Samples 
were stored at −20°C until ready to perform hybridization. 30 
Table 1 Frequency of MN formation in NRK-52E cells treated 
with GTX, GTX/S9 and NGTX chemicals 
 
Class Compound name  
and compound dose 
% MN formation 
 
Control 
DMSO 0.26 ± 0.04 
Medium 0.27 ± 0.03 
S9 alone 0.27 ± 0.15 
 
 
GTX 
AA (1.65μM) 0.54 ± 0.11 * 
BaP (40μM) 0.54 ± 0.04 ** 
BaP (87μM) 1.40 ± 0.97 
BaP/S9 (87μM) 4.00 ± 0.70 * 
2NF(20μM) 0.18 ± 0.07 
2NF (70μM) 0.50 ± 0.35 
2NF/S9 (70μM) 0.90 ± 0.72 
KBrO3 (500μM) 6.63 ± 1.37 * 
NDMA (1mM) 0.32 ± 0.15 
STZ (350μM) 0.20 ± 0.10 
STZ/S9 (350μM) 0.80 ± 0.56 
 
NGTX 
BDCM (0.47mM) 0.18 ± 0.10 
CHL (1.1μM) 0.20 ± 0.20 
DCVC (3μM) 0.16 ± 0.16 
MON (250μM) 0.32 ± 0.34 
OTA (0.5μM) 0.23 ± 0.10 
Results are mean ± SD with at least three different cell cultures per measurement. 
Statistically significantly different from appropriate control, * p< 0.05, ** P<0.01 35 
 
Hybridization 
cRNA targets were hybridized on high-density oligonucleotide 
gene chips (Affymetrix GeneChip Rat Genome 230 2.0 Arrays) 
according to the Affymetrix Eukaryotic Target Hybridization 40 
manual. The gene chips were washed and stained using the 
Affymetrix Fluidics Station 450 and Genechip Operating 
Software and scanned by means of an Affymetrix GeneArray 
scanner.  
Microarray analysis  45 
The intensity values of different genes (probe sets) generated by 
Affymetrix GeneChip Operating Software were imported into 
Genedata Expressionist® version 7.0 and GeneSpring version 11 
software (Agilent), respectively, for data analysis. The raw data 
files (.CEL files) containing signal values for individual probes 50 
were pre-processed to generate one value per probeset. Pre-
processing of arrays was done using GC-RMA (Robust 
Multiarray Analysis algorithm). To identify the differentially 
expressed genes, the condensed data were subjected to pairwise 
comparisons, using paired t-test. Comparisons were made 55 
between control and treated samples. Only genes with >2-fold 
change, using a p < 0.001 threshold value were analyzed. 
Functional annotation 
To understand the biological meaning behind the list of 
differentially expressed genes, KEGG (Kyoto Encyclopaedia of 60 
Genes and Genomes database) pathways analysis and GO (Gene 
Ontology) from DAVID website (The Database 
for Annotation, Visualization and Integrated Discovery) v 6.7 
was used (http://david.abcc.ncifcrf.gov/)16. The list of 
differentially expressed probe sets (DEPs) obtained from the 65 
GeneSpring v.11 was uploaded and run for enriched GO and 
KEGG pathways. Only GO and pathways with p <0.05 were 
analysed and discussed.  
Results 
Selection of exposure dose 70 
These studies was aimed at detecting the early carcinogenic 
potential of eleven renal carcinogens in vitro, thus NRK-52E cells 
were exposed to a single dose that caused 10% cytotoxicity (IC10) 
at 72h. Three exposure time points were selected 6h, 24h and 72h 
exposure effects. Cytotoxicity studies showed that 81% of the 75 
selected compounds (13/16) were cytotoxic to NRK-52E cells, 
the cytotoxicity being time and dose-dependent. All NGTX 
compounds were toxic to NRK-52E cells, whereas two 
compounds from the GTX group (STZ and NDMA) and one from 
the NC group (MAN) exhibited no cytotoxicity at the highest 80 
concentration tested. The most toxic compounds were OTA 
followed by CHL > AA > DCVC > DS > BaP > NIF > 2NF > 
MON > TOL > BDCM > KBrO3 > CLO. In addition to 
cytotoxicity, the in vitro cytokinesis-block micronucleus assay 
was used to assess if the dose used had any effect on DNA. The 85 
assay confirmed the lack of  clastogenicity with NGTX 
compounds, as none of the five NGTX compounds induced 
micronuclei (MN) formation (Table 1). In the GTX group 
chromosomal damage was increased with KBrO3, AA and BaP 
(Table 1). In addition, MN formation was examined after 90 
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exposure to three GTX compounds BaP, 2NF and STZ in the 
presence of a rat liver β-naphthoflavone-induced S9 drug 
metabolising system. S9 alone after heat-incubation step caused 
10% cytotoxicity CHECK IT. A statistically significant increase 
in MN formation was seen after exposure to BaP in the presence 5 
of S9 (Table 1), while in the absence of S9 there was a small 
increase which was not statistically significant (Table 1). There 
was a trend for an increase in MN formation with 2NF and STZ 
in presence of S9 but this was not statistically significant (Table 
1). 10 
 
Table 2 Number of DEPs and enriched KEGG pathways 
identified after GTX carcinogen, NGTX carcinogen and NC 
exposure to NRK-52E cells for 6h, 24h and 72h 
 15 
   
CLASS          
COMPOUND 
NAME AND IC10 
DOSE  
 
NUMBER OF DEPS 
ENRICHED 
KEGG 
PATHWAYS 
(P<0.05) 
  6h 24h 72h  
 
GTX 
AA (1.65μM) 3 8 78 p53 signalling,  
Pathways in 
cancer, 
Ubiquitin 
mediated 
proteolysis  
BaP (40μM) 11 1 1 - 
KBrO3 (500μM) 1 8 57 - 
2NF (20μM) 6 0 0 - 
NDMA (1mM) 10 0 21 - 
STZ (350µM) - - 9 - 
 
NGTX 
BDCM (0.47mM) 0 0 2 - 
 
CHL (1.1μM) 
 
 
 
174 
 
 
 
324 
 
 
 
 
317 
 
 
 
MAPK 
signalling, Toll-
like receptor 
signalling, Cell 
cycle, Steroid 
biosynthesis, 
Biosynthesis of 
unsaturated 
fatty acids, 
Proteasome 
assembly, 
Pathways in 
cancer, 
Terpenoid 
backbone 
biosynthesis, 
Focal adhesion, 
Ubiquitin 
mediated 
proteolysis  
 
DCVC (3μM) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0 
 
1 
 
1448 
Aminoacyl-
tRNA 
biosynthesis, 
Cell cycle, 
Ubiquitin 
mediated 
proteolysis, 
Regulation of 
actin 
cytoskeleton, 
Endocytosis, 
Pyrimidine 
metabolism,  
Pathways in 
cancer, Protein 
export, 
spliceosome, 
Focal adhesion, 
p53 signalling, 
Valine, leucine 
and isoleucine 
biosynthesis, 
mTOR 
signalling 
MON (250μM) 6 24 123 Mevalonate 
kinase pathway  
OTA (0.5μM) 
 
 
 
 
 
 
 
 
 
 
 
170 
 
 
 
 
 
 
 
 
 
 
1057 
 
 
 
 
 
 
 
 
 
 
723 
 
 
 
 
 
 
 
 
 
 
Pyrimidine 
metabolism, 
Purine 
metabolism, 
Cell cycle, 
WNT-
signalling, p53 
signalling, 
Spliceosome, 
Steroid 
biosynthesis, 
Fructose and 
mannose 
metabolism, 
Pathways in 
cancer, Renal 
cell carcinoma, 
Sphingolipid 
metabolism, 
Lysosome 
 
NC 
CLO (1.12mM) 42 16 46 Steroid 
biosynthesis 
DS  (16μM) 7 1 22 - 
MAN (10mM) 1 2 94 Focal adhesion 
NIF (35μM) 4 1 0 - 
TOL (0.37mM) 0 4 31 Tight junction 
 
   
Table 3 DEPs commonly altered after GTX or NGTX carcinogen 
exposure to NRK-52E cells 
 20 
ENTREZ 
GENEID 
GENE DEREGULATION 
AFTER EXPOSURE 
314856 Mdm2 (p53 binding 
protein homolog 
(mouse)  
AA (72h), BaP/S9 (72h), 
2NF/S9 (72h), STZ/S9 
(72h), CHL (24h),  
DCVC (72h) 
114851 p21 (Cyclin-
dependent kinase 
inhibitor 1A) 
AA (72h), KBrO3 (24h), 
BaP/S9 (72h),  
2NF/S9 (72h),OTA (24h) 
64036 Cd55 (Decay 
accelerating factor 
for complement 5)  
KBrO3 (72h), BaP/S9 
(72h), 2NF/S9 (72h) 
STZ/S9 (72h), OTA(72h) 
25240 Aqp1 (Aquaporin 1)  AA (72h), BaP/S9 (72h), 
DCVC (72h), OTA (72h) 
Transcriptomics studies 
Transcriptome analysis revealed that the response of the NRK-
52E cells to GTX carcinogens and NC compounds was far less 
pronounced than to NGTX carcinogens (Table 2). BDCM 
(NGTX) and NDMA (GTX) had a marginal effect on the 25 
transcriptome profile and as both compounds were volatile at 
370C, the exact exposure concentration was uncertain and thus 
both chemicals were not included in the analysis. In total, 
transcriptomic analysis has been conducted on five GTX 
carcinogens, four NGTX carcinogens and five NC compounds. 30 
Exposure to the five GTX carcinogens altered 214 genes in total 
over 6h, 24h and 72h, while exposure to the five NC altered a 
total of 271 genes. In contrast, exposure to the four NGTX 
carcinogens altered the expression of > 4,000 genes (Table 2). In 
agreement with previous studies, there was generally a time-35 
dependent increase in the number of differentially expressed 
genes17-18.  
Carcinogenic versus non-carcinogenic compounds 
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There were no common genes altered by all of the renal 
carcinogens (GTX+NGTX), including the three GTX compounds 
tested in the presence of a S9 metabolising system. However, 
three genes Mdm2 (MDM2 p53 binding protein), p21 (Cyclin-
dependent kinase inhibitor 1) and Cd55 (Decay accelerating 5 
factor for complement), were commonly altered by 6 out of 9 
compounds (67%) in case of Mdm2 and by 5 out of 9 compounds 
(56%) in case of p21 and Cd55 (Table 3). The deregulation 
primarily occurred at the later time point (Table 3). In addition, 
Aqp1 (Aquaporin 1) was altered by two GTX and two NGTX 10 
compounds after 72h exposure (Table 3). None of these genes 
were altered at any time point by the five NC compounds.   
Non-genotoxic compounds 
. No commonly deregulated genes were induced by all four 
NGTX carcinogens at 6h, 24h or 72h. However, five genes with 15 
the same pattern of expression (except Usp9x) were commonly 
deregulated after 72h exposure to CHL, DCVC and OTA namely: 
Lingo1 (Leucine rich repeat and Ig domain containing 1), Hmox1 
(Heme oxygenase, decycling 1), Ssu72 (Ssu72 RNA polymerase 
II CTD phosphatase), Lyrm1 (LYR motif containing 1) and 20 
Usp9x (Ubiquitin specific peptidase 9, X-linked) (Table 4).  
 
Table 4 List of DEPs commonly deregulated after 72h exposure 
of NGTX carcinogens to NRK-52E cells 
 25 
↑ up-regulation ↓down-regulation 
 
Pathways analysis in the NGTX class 
It is widely acknowledged that tumorogenesis is driven by 
disruption in pathways rather than individuals genes19, thus 30 
similarities in the pathways affected by NGTX carcinogen 
exposure were investigated. Exposure to NGTX carcinogens 
predominantly up-regulated genes involved in signalling 
pathways, whereas genes involved in metabolism were 
predominantly down-regulated.  35 
Three NGTX carcinogens affected  cell cycle pathways, at 
different time points CHL, 6h; OTA, 24h and DCVC 72h, with 
common deregulation of genes from the GADD45 family 
(Growth arrest and DNA-damage-inducible). Intriguingly, both 
CHL and DCVC up-regulated Gadd45 genes whereas OTA 40 
exposure down-regulated them. Additionally, three genes were 
commonly altered after DCVC and OTA exposure these were, 
Mad2l2 (MAD2 mitotic arrest deficient-like2), Rad21 (RAD21 
homolog, S. pombe) and Rbx1 (Ring-box 1). Mad2l2 is a 
component of the mitotic spindle assembly checkpoint that 45 
prevents the onset of anaphase until all chromosomes are 
properly aligned at the metaphase plate. Interestingly, Mad2l2 
and Rad21 were up-regulated and Rbx1 down-regulated after 
DCVC exposure, while with OTA, Mad2l2 and Rad21 were 
down-regulated and Rbx1 was up-regulated.  In addition to the 50 
cell cycle pathway, CHL (72h), DCVC (72h) and OTA (24h) 
exposure also significantly enriched cancer pathways, with three 
genes commonly deregulated from the Frizzled and Integrin 
family and Tcf (Similar to transcription factor 7-like 2, T-cell 
specific). The canonical p53 signalling pathway was also 55 
enriched after 72h exposure to DCVC and 24h exposure to OTA, 
with two commonly altered genes, Rrm2 (Ribonucleotide 
reductase M2) and Gadd45. CHL and DCVC enriched the focal 
adhesion pathway with two commonly deregulated genes; Pak1 
(p21 protein (Cdc42/Rac)-activated kinase 1) and Akt3 (V-akt 60 
murine thymoma viral oncogene homolog 3). Genes from the 
Integrin and Laminin family were also commonly deregulated by 
CHL and DCVC. 
In addition, OTA (24h) enriched WNT-signalling and the renal 
cell carcinoma pathway, while DCVC (72h) altered the mTOR 65 
pathway and CHL (6h) enriched the MAPK signalling pathway 
(Table 2). MON did not alter any canonical cancer pathways, but 
down-regulated the mevalonate kinase pathway (Table 2).  
 
Table 5 Number of DEPs and enriched KEGG pathways 70 
identified after 72h exposure to GTX and GTX/S9 in NRK- 52E 
cells 
 
COMPOUND 
NAME AND 
DOSE 
NUMBER OF  
DEPS 
ENRICHED KEGG  
PATHWAYS(P<0.05) 
BaP (87µM) 1 - 
 
BaP/S9 (87µM) 
 
93 
MAPK signalling, Focal 
adhesion,  
Pathways in cancer 
2NF (70µM) 87 p53 signalling pathway  
 
2NF/S9 (70µM) 
 
110 
p53 signalling, Aminoacyl-
tRNA biosynthesis, 
Porphyrin metabolism, 
Glycine, serine and 
threonine metabolism,  
Cell cycle 
STZ (350µM) 9 - 
STZ/S9 (350µM) 58 p53 signalling pathway 
 
Genotoxic compounds 75 
. In the GTX class there were no commonly genes identified at 
any time point with AA, BaP, 2NF, STZ and KBrO3 or BaP, STZ 
or 2NF in the presence of S9.  
AA was the only compound (from the GTX without S9) that 
enriched cancer related pathways (Table 2). BaP and 2NF had a 80 
very small effect on the transcriptome profile, whereas exposure 
to KBrO3 altered 66 genes over 72h (Table 2). As BaP and 2NF 
are known pro-carcinogen’s that need to be metabolized to DNA 
reactive proximate carcinogens to exert their carcinogenic 
potential, an external metabolic activation system, β-85 
naphthoflavone-induced rat liver S9 was used. Exposure of NRK-
52E cells to S9 alone altered genes involved mainly with 
immunological functions: NOD-like receptor and chemokine 
signalling suggestive of an immune response. No genes involved 
ENTREZ 
GENEID 
 
GENE NAME 
REGULATION PATTERN 
(FOLD CHANGE 
TREATED V CONTROL) 
CHL DCVC OTA 
24451 Hmox1 (Heme 
oxygenase, decycling 
1) 
39.53 ↑ 40.97 ↑ 3.14 ↑ 
298681 Ssu72 (Ssu72 RNA 
polymerase II CTD 
phosphatase) 
2.45 ↑ 2.3 ↑ 2.15 ↑ 
365361 Lyrm1 (LYR motif 
containing 1) 
3.68 ↑ 7.0 ↑ 3.57 ↑ 
315691 Lingo1 (Leucine rich 
repeat and Ig domain 
containing 1)  
6.52↓ 18.11↓ 2.38↓ 
363445 Usp9x (Ubiquitin 
specific peptidase 9, 
X-linked) 
2.87↓ 5.47↓ 2.25 ↑ 
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in cancer-related pathway were altered in the presence of S9. AA 
was not studied in the presence of S9 as nitro-reduction is 
primarily involved in the activation while oxidation via CYP1A1 
has been shown to protect against the carcinogenic effect of 
AA20. In general, exposure to GTX compounds (BaP, 2NF and 5 
STZ) together with induced S9 increased the number of DEPs 
and helped to predict their carcinogenic potential (Table 5).  
Five genes with the same pattern of expression were found to be 
commonly deregulated by BaP, 2NF and STZ after prior external 
metabolic activation; Mgmt (O-6-methylguanine-DNA 10 
methyltransferase), Epoh1 (Epoxide hydrolase 1), Scarb2 
(Scavenger receptor class B, member 2), Jam3 (Junctional 
adhesion molecule 3) and Cd55 (Table 6). However, from these 
five deregulated genes, three were also deregulated by NGTX 
carcinogens. Cd55, in addition to being down-regulated by BaP, 15 
STZ and 2NF after metabolic pre-incubation, was also down-
regulated by KBrO3 and by the NGTX carcinogen OTA, whereas 
Mgmt and Scarb2 were up-regulated by DCVC exposure. Thus it 
is much more difficult to find a set of specific genes deregulated 
by the GTX carcinogens.  20 
In addition, no commonly deregulated genes were found to be 
altered by GTX carcinogens exposure, that were positive for MN 
induction (AA, KBrO3 and BaP/S9) after 72h exposure.  
 
Table 6 List of genes common deregulated after 72h of BaP/S9, 25 
2NF/S9 and STZ/S9 exposure in NRK-52E cells 
 
 
ENTREZ 
GENEID 
 
     GENE NAME 
 
 
REGULATION PATTERN 
(FOLD CHANGE TREATED 
VS CONTROL) 
BaP/S9 2NF/S9 STZ/S9 
25332 Mgmt (O6-
methylguanine DNA 
methyltransferase) 
3.78↑ 2.74↑ 2.98↑ 
117106 Scarb2 (Scavenger 
receptor class B, 
member 2) 
2.34↑ 2.2↑ 2.14↑ 
25315 Epoh1 (Epoxide 
hydrolase 1) 
3.87↑ 5.33↑ 3.53↑ 
315509 Jam3 (Junctional 
adhesion 
molecule 3) 
3.0↑ 3.21↑ 2.67↑ 
64036 Cd55 (Decay 
accelerating factor 
for complement 5) 
4.92↓ 6.27↓ 8.07↓ 
↑ up-regulation ↓down-regulation 
 
Pathway analysis of GTX carcinogens after S9 exposure 30 
BaP exposure after metabolic activation (BaP/S9) increased of 
number of DEPs and significantly enriched pathways associated 
with cancer such as the MAPK signalling and focal adhesion 
(Table 5). STZ after metabolic activation (STZ/S9) also increased 
the number of DEPs as compared to STZ alone and significantly 35 
enriching the p53 signalling pathway (Table 5). Results with 2NF 
were more ambiguous, with a slight increase in the number of 
DEPs and enrichment of more diverse set of pathways including 
cancer pathways.  
Discussion 40 
The rat renal normal epithelial cell line (NRK-52E) was selected 
for this work with the main aim being to find an alternative model 
system to classify compounds according to their carcinogenic 
potential to the kidney. As the majority of the current 
carcinogenic data derives from rodents (mainly rats), NRK-52E 45 
cells were the preferred cell line. The current evaluation of 
carcinogenicity of chemicals relies heavily on different animal in 
vivo and in vitro methods, with NGTX carcinogens being 
especially problematic.  
In this work eleven chemicals that cause renal tubule tumours in 50 
rats have been evaluated. Six of them have previously been 
shown to act via a GTX mechanism and five chemicals are 
thought to act by a NGTX mechanism10. Additionally five NC 
had been used as controls. Cytotoxicity studies were conducted 
using all 16 chemicals on NRK-52E cells, to assess the effect that 55 
these chemicals had on the cells. Determination of cytotoxicity is 
an initial step toward the characterisation of chemicals. 
Although cytotoxicity assays per se does not provide mechanistic 
data, they shed light on cell response/susceptibility to 
investigated cytotoxins. Furthermore, knowledge of the 60 
concentration range that induces cytotoxicity enables better 
definition of concentrations to be employed in more in-depth 
descriptive and mechanistic studies such as gene expression 
profiling. As the main aim of the project was to try to detect an 
early carcinogenic potential of the selected compounds, the 65 
endpoint of interest was carcinogenicity not cytotoxicity, the 
selected dose that cause only 10% cytotoxicity (IC10) and thus 
have small but visible effect on the cell line was used. For 
transcriptomics, only one dose was investigated, but with 
different times of exposure. The reason for this being the analysis 70 
of previous published studies, showing that in in vitro models, 
treatment time has a much larger impact on gene expression than 
the chemical’s dose21-22. Three time points were selected to 
provide additional data 6h, 24h and 72h . The early exposure time 
point (6h) was selected as GTX chemicals have been shown to 75 
induce DNA damage and repair in a matter of few hours after 
administration23-24. As the main aim of this study was to look at 
the carcinogenicity of the chemical and 1/3 of the chemicals used 
are known to be DNA-reactive, the in vitro micronucleus assay 
was used to assess if the dose used (IC10) had any effect on  80 
DNA. The assay confirmed the lack of  clastogenicity with 
NGTX chemicals (Table 1). In the GTX group, chromosomal 
damage was proven for KBrO3, AA and BaP. The clastogenicity 
after KBrO3 exposure is believed to be due to oxidative stress, 
increased reactive oxygen species, glutathione depletion25 and 8-85 
OHdG formation leading to double strand breaks in the DNA26-27. 
AA has also been shown to increase MN formation in mouse 
bone marrow cells28, human lymphocytes exposed to the plant 
extract from Aristolochia29 and HepG2 cells30. A small, but 
statistically significant, induction of MN was seen with BaP 90 
(Table 1). BaP is known to require metabolism by cytochrome 
P450 to undergo metabolic activation31 and as NRK-52E cells do 
not possess functional cytochrome P450 (as quantified by HPLC-
MS/MS with a range of different substrates, Bloch, unpublished 
results) this finding was unexpected, but may be explained by 95 
photoactivation of the chemical32. A statistically significant 
increase in MN formation was observed after the addition of a 
xenobiotic drug metabolising system in case of BaP and a small 
but not statistically significant increase was noted after 2NF/S9 
and STZ/S9 (Table 1).   100 
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Carcinogen detection 
Although it was not possible to find a set of genes that was 
commonly deregulated by all five GTX carcinogens and by all 
four NGTX carcinogens, Mdm2, p21 and Cd55 were commonly 
altered by five or more carcinogens (Table 3). Mdm2 and p21 5 
were proposed by Ellinger-Ziegelbauer33 as a gene signature for 
GTX exposure in rat liver, however we observed that CHL, OTA 
and DCVC also altered the expression of the aforementioned 
genes (Table 3). CD55 is one of the complement 
regulatory/inhibitory proteins and is altered in a wide range of 10 
solid tumours34. Interestingly Aqp1 was also altered by GTX and 
NGTX carcinogens and recently Aqp1 has been proposed as a 
renal cancer biomarker35.  
Additionally examination of pathways enriched by chemical 
exposure, showed that 3 out of 4 (75%) NGTX carcinogens and 4 15 
out of 5 (80%) GTX carcinogens (AA, BaP/S9, 2NF/S9, STZ/S9, 
with KBrO3 being the only chemical that did not enriched any 
pathway) were related to known pathways involved in 
carcinogenesis. In contrast, none of the NC chemicals induce any 
of the well-established carcinogenic pathways. Mannitol and 20 
BaP/S9 both increased 4 and 5 genes respectively in the focal 
adhesion pathway, however there was only one common gene 
coll1α1. So far gene expression profiling studies using cancer 
related pathways has shown a detection rate of 78% for renal 
carcinogens (7/9) under the conditions of these studies. 25 
The enriched pathways that were affected by two or more 
carcinogens include; p53 signalling pathway (AA, 2NF/S9, 
STZ/S9, DCVC and OTA), pathways in cancer (AA, BaP/S9, 
CHL, DCVC and OTA), cell cycle (2NF/S9, DCVC and OTA), 
focal adhesion (BaP/S9, CHL and DCVC), MAPK signalling 30 
pathway (BaP/S9 and CHL). Thus, this study has shown that 
NRK-52E, rat renal cell model has a potential for detecting renal 
carcinogens in vitro. MON was the only NGTX compound that 
did not altered any canonical cancer related pathways. However, 
using a less stringent p value of <0.01 MON increased pathways 35 
in cancer, renal cell carcinoma and the cell cycle 72h after 
exposure..   
As mentioned above there is a real problem of early detection of 
NGTX carcinogens. In NRK-52E cells, exposure to three of the 
four compounds (except for MON) commonly deregulated five 40 
genes, Lingo1, Hmox1, Ssu72, Lyrm1 and Usp9x (Table 4)36. 
Lingo1 is currently implicated in oligodentrocyte differentiation 
and axonal myelination and no study so far have shown its 
involvement in carcinogenesis. HMOX1 which is under the 
regulation of Nrf2, plays an important role in oxidative injury37 45 
and has been shown to regulate cell proliferation, modulate 
inflammatory response and facilitate angiogenesis38. Ssu72 
encodes a protein involved in RNA processing and termination. 
Little is known about the function of LYRM1, although Qiu et 
al.39 has shown that the protein is involved in modulation of cell 50 
growth and apoptosis in pre-adipocytes. USP9X is a member of 
the peptidase family that regulate the production and recycling of 
ubiquitin which are involved in the control of cell growth, 
differentiation and apoptosis40. NGTX carcinogens 
predominantly up-regulated genes involving in signalling 55 
pathways, whereas genes involved in metabolism were 
predominantly down-regulated.  
This finding agrees with studies analysing gene expression in 
human clear cell renal carcinoma, where loss of normal renal 
function, downregulation of metabolic genes and alteration in 60 
multiple canonical cancer-associated pathways occurs, including 
cell cycle, focal adhesion, ECM-interaction and disruption in 
amino-acid metabolism41-42. Additionally as mentioned above 
three NGTX carcinogens commonly deregulated the cell cycle 
pathway with common deregulation of genes from the GADD45 65 
family. Proteins encoded by these genes are DNA-damaging 
sensor proteins, with up regulation of expression after a DNA-
damaging event. They interact with both CDK1 (Cyclin-
dependent kinase 1) and CCNB1 (Cyclin B1), resulting in 
inhibition of the kinase activity of the CDK1/CCNB1 complex, 70 
and function as a negative growth control. In addition, all three 
NGTX deregulated different cancer pathways such as WNT-
signalling, renal cell carcinoma pathway, mTOR pathway and 
MAPK signalling pathway (Table 2).  
GTX compounds, except from AA, without prior metabolic 75 
activation altered a much smaller number of genes as compared 
to NGTX compounds and did not alter cancer related pathways. 
Thus an external metabolising system was used to improve the 
metabolic capabilities of the NRK-52E cells. Pre-incubation with 
an induced rat liver S9 fraction was shown to improve the 80 
detection of carcinogenic potential of GTX compounds (Table 5). 
Following BaP/S9, 2NF/S9 and STZ/S9 exposure five genes were 
found to be commonly deregulated; Mgmt, Scarb2, Epoh1, Jam3 
and Cd55 (Table 6). Mgmt encodes an enzyme that repairs 
alkylated guanine in DNA. STZ is a known alkylating agent, 85 
while BaP and 2NF are not, however Ellinger-Ziegelbauer and 
coworkers reported an increase in Mgmt after in vivo exposure to 
2NF and other GTX compounds43. While Grombacher and 
coworkers showed that p53 regulates Mgmt expression and that 
Mgmt is induced after GTX stress, being one of the first DNA 90 
repair gene to be up-regulated44. Epoh1 is a critical enzyme in 
xenobiotic detoxiﬁcation, which catalyzes the hydrolysis of arene 
and aliphatic epoxides to less reactive and more water soluble 
dihydrodiols.  However, EPOH1 has been shown to activate BaP 
to mutagenic and carcinogenic products and Epoh1 95 
polymorphisms have been associated with the onset of numerous 
cancers45-47. Scarb2 encodes a transmembrane glycoprotein that is 
located in lysosome and endosome membranes and may 
participate in membrane transportation and the reorganization of 
endosomal/lysosomal compartments. Huang and coworkers 100 
reported the loss of heterozygosity in Scarb2 in human 
hepatocellular carcinoma48. Jam3 encodes a protein that is 
expressed in close proximity to tight junctions of polarized 
endothelial and epithelial cells and also mediates cell adhesive 
events between tumour cells and the endothelium49.  105 
In addition, cancer–related pathways were also enriched with 
induction of the p53 signalling pathway after STZ/S9 and 2NF/S9 
exposure and MAPK signalling after BaP/S9 exposure. 
Enrichment of MAPK signalling pathway after BaP exposure has 
also been reported by others 50-52. MAPK signalling pathway was 110 
also enriched after 6h exposure to CHL (NGTX), although only 
one gene Gadd153 was commonly up-regulated by both 
compounds. Although the addition of the S9 fraction greatly 
improved the response to BaP and STZ, with 2NF/S9 the results 
were more ambiguous. 2NF (40μM) alone altered 6 genes over 115 
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72h, however increasing the dose to 70μM led to 87 genes being 
altered while the addition of S9 to 2NF (70μM) led to 110 genes 
being altered. This suggests in the case of 2NF that the dose was 
more important than metabolic pre-incubation. However, closer 
examination revealed that although the higher concentration 5 
induced more DEPs, the DE genes altered after exposure to 2NF 
alone were involved in apoptosis in contrast to 2NF/S9 exposure 
where the genes were primarily involved in metabolism (amino 
acid transport, amino acid activation and cholesterol 
biosynthesis). In addition, there were some similarities after 10 
exposure to 2NF (70μM) with and without S9; ten commonly 
deregulated genes associated with cancer and a significant 
enrichment of the p53 signalling pathway. In addition, exposure 
to 2NF/S9 enriched four pathways namely aminoacyl-tRNA 
biosynthesis, glycine, serine and threonine metabolism and 15 
porphyrin metabolism, all being down-regulated (Table 5).  
 
Table 7 KEGG pathways enriched after GTX exposure 
 
 
KEGG Pathway 
No of genes 
involved in 
the pathway 
 
P-value 
p53 signalling pathway 9 4.1E-5 
Pathways in cancer 17 4.6E-4 
Small cell lung cancer 7 5.8E-3 
ErbB signalling pathway 7 6.6E-3 
Melanoma 6 1.2E-2 
Cell cycle 8 1.2E-2 
MAPK signalling pathway 12 1.6E-2 
Glycine, serine and threonine 
metabolism 
4 2.5E-2 
Terpenoid backbone biosynthesis 3 3.0E-2 
Ubiquitin mediated proteolysis 7 3.9E-2 
Aminoacyl-tRNA biosynthesis 4 4.4E-2 
 20 
Table 8 KEGG pathways enriched after NGTX exposure 
 
                 
         KEGG Pathway 
No of genes 
involved in the 
pathway 
 
    P-value 
Cell cycle 41 7.2E-8 
Steroid biosynthesis 11 1.5E-5 
Aminoacyl-tRNA biosynthesis 17 2.7E-5 
Spliceosome 34 3.8E-5 
Pyrimidine metabolism 27 1.3E-4 
p53 signalling pathway 21 2.8E-4 
Terpenoid backbone biosynthesis 8 1.1E-3 
Ubiquitin mediated proteolysis 30 2.2E-3 
Sphingolipid metabolism 13 7.7E-3 
Pathways in cancer 58 1.2E-2 
RNA polymerase 9 1.8E-2 
Porphyrin metabolism 10 1.8E-2 
Fatty acid metabolism 12 2.0E-2 
Glycine, serine and threonine 
metabolism 
10 2.2E-2 
Protein export 5 2.4E-2 
Amino and nucleotide sugar 
metabolism 
12 2.4E-2 
Small cell lung cancer 19 2.6E-2 
RNA degradation 14 3.7E-2 
DNA replication 10 3.8E-2 
Renal cell carcinoma 16 3.9E-2 
Colorectal cancer 18 4.0E-2 
Focal adhesion 36 4.4E-2 
Arginine and proline metabolism 13 4.6E-2 
Regulation of actin cytoskeleton 38 4.7E-2 
WNT signalling pathway 28 4.8E-2 
 
Genotoxic versus non-genotoxic carcinogens 
Overall, many more genes were deregulated after NGTX 25 
exposure. The reason for this could be that NGTX have a more 
diverse MOA, or simply do not need metabolic activation. 
However, genes traditionally connected with GTX exposure like 
Gadd45, Gadd153, Mdm2, p21 and Mgmt were up-regulated by 
exposure to NGTX carcinogens CHL, DCVC and OTA. When 30 
the list of all differentially expressed genes induced by exposure 
to the four NGTX carcinogens, at the three time points and the 
six GTX carcinogens with and without previous metabolic 
activation at the three time points were pooled, pathway 
enrichment analysis showed that there was no major differences 35 
between these two groups (Tables 7 and 8). In general, the 
pathways affected by GTX carcinogens were also affected by 
NGTX carcinogens, although not all pathways enriched by 
NGTX were enriched after GTX exposure. The unaffected 
pathways were mainly intermediary metabolism pathways for 40 
amino acids, carbohydrates and lipids. This may be explained by 
a more diverse MOA and thus the larger number of genes 
affected after NGTX exposure. The motivation behind 
classification into GTX and NGTX class is risk assessment based. 
NGTX carcinogens are thought to be less hazardous to human 45 
health than GTX, with a threshold for NGTX exposure and no 
threshold value for GTX carcinogen exposure. However, some 
studies have suggested that there might also be a threshold for 
GTX exposure53-54. This study using NRK-52E cells has 
demonstrated that it is difficult to separate GTX from NGTX 50 
carcinogens. This might be due to incorrect classification of a 
compound(s) e.g. OTA55, inherent limitation of the in vitro model 
system used, or the small number of compounds tested. Despite 
these limitations, the data presented here shows that gene 
expression profiling in NRK-52E cells is a promising model tool 55 
which used in conjunction with an external metabolising system 
can provide valuable information on the  potential carcinogenicity 
of chemicals.  
In summary, we have been able to detect renal carcinogens using 
pathway analysis with a success rate of 78% for 9 carcinogens, 60 
using an S9 drug metabolising system for the GTX compounds. 
In addition we could clearly separate these carcinogens  from 5 
NC. With regard to separating GTX from NGTX carcinogens we 
identified several common pathways for both classes, making it 
difficult to separate direct acting carcinogens from the indirect 65 
acting of carcinogens.  
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